NextCure reports FY 2021 net loss of $69.4M; cash $219.6M, expects funding into Q1 2024

NextCure, Inc.

Net loss $69.4M in 2021 vs $36.6M in 2020; no revenue recognized (Eli Lilly agreement ended).
Cash, equivalents, marketable securities $219.6M at Dec 31, 2021, down $63.8M; expected to fund ops into Q1 2024.
R&D expenses $50.2M in 2021 vs $46.6M; G&A $20.6M vs $17.0M primarily from headcount increases.
Multiple 2022 data readouts planned: NC318 Phase 2 update Q4, NC410 update H2, NC762 initial Phase 1 data H2, NC525 IND filing Q4.
COVID-19 pandemic delayed clinical trial enrollment, causing some milestones to be pushed back.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.